Outset Medical (NASDAQ:OM) Upgraded at Wall Street Zen

Outset Medical (NASDAQ:OM) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

OM has been the topic of several other reports. Stifel Nicolaus decreased their price target on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 7th. BTIG Research reissued a “buy” rating and issued a $17.00 target price on shares of Outset Medical in a research note on Tuesday, December 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

Outset Medical Stock Down 1.2%

NASDAQ OM opened at $5.01 on Friday. The business has a fifty day moving average price of $4.40 and a 200 day moving average price of $10.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.77 and a current ratio of 7.09. The company has a market cap of $90.95 million, a P/E ratio of -0.38 and a beta of 2.07. Outset Medical has a one year low of $3.10 and a one year high of $21.98.

Insider Transactions at Outset Medical

In other news, CEO Leslie Trigg sold 11,794 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $60,385.28. Following the transaction, the chief executive officer directly owned 107,823 shares in the company, valued at approximately $552,053.76. This represents a 9.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel John L. Brottem sold 9,314 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $47,687.68. Following the transaction, the general counsel directly owned 36,957 shares of the company’s stock, valued at $189,219.84. The trade was a 20.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 35,989 shares of company stock worth $180,073. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Outset Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OM. Legal & General Group Plc purchased a new position in shares of Outset Medical during the second quarter worth $34,000. Ameritas Investment Partners Inc. acquired a new position in Outset Medical in the 2nd quarter valued at about $35,000. BNP Paribas Financial Markets grew its position in Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after acquiring an additional 2,034 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in Outset Medical during the second quarter worth about $78,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Outset Medical during the second quarter worth about $108,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.